Shots:
- The US FDA has granted FTD to ADI-001 for treating adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement
- Adicet Bio is advancing ADI-001 in six autoimmune indications, with patient enrollment ongoing in the P-I LN study. Enrollment in SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM, or myositis), and stiff person syndrome (SPS) will start in Q1’25, with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) enrollment expected in H2’25
- The P-I (GLEAN) trial demonstrated robust exposure and complete CD19+ B-cell depletion as ADI-001 targets B-cells via an anti-CD20 CAR
Ref: Businesswire | Image: Adicet Bio
Related News:- The US FDA grants RMAT Designation to Gradalis’ Vigil for Advanced Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
